Potential new treatment for breast cancer

UniSC Clinical Trials is working with Roche on a new phase 3 study for patients with HER2-positive breast cancer. This study is evaluating the efficacy and safety of inavolisib in combination with phesgo® versus placebo in combination with phesgo® as maintenance therapy after first line induction therapy in patients with PIK3A-mutated HER2 positive locally advanced or metastatic breast cancer.

The trial will take place at our clinic at Sunshine Coast Haematology and Oncology Clinic in Buderim with Principal Investigator Dr Brenton Seidl overseeing the study.

We are looking for people who:

• are aged 18 years or older
• have HER2-positive breast cancer that has spread (locally advanced or metastatic)
• are willing and able to comply with study visits

If you have any patients who fit the criteria, we would appreciate your consideration of their participation in this trial.

Participation will be of no cost; private health insurance is not required.